Patents Assigned to GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD.
-
Patent number: 11796443Abstract: The present invention discloses a method for isolating placental trophoblast cells from cervical exfoliated cells of a pregnant woman. Based on a specific antigen or combination expressed on the surface or inside of specific trophoblast cells, the designed microfluidic sorting chip or flow cytometer is used in the method to perform cell sorting of a cell suspension of a placental trophoblast sample, thus obtaining isolated and purified placental trophoblast cells. Compared with conventional methods, the method of the present invention has the advantages of non-invasively obtaining specimens and good specificity. Moreover, the method causes low risk of infection and abortion, allows earlier sampling time and can achieve the synchronous labeling of a plurality of antigens as well as identification and sorting of characteristic fluorescence signals; and the method has greatly improved accuracy and higher reliability and broader coverage area of detection results.Type: GrantFiled: March 16, 2022Date of Patent: October 24, 2023Assignees: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGDONG HYBRIBIO BIOTECH CO., LTD.Inventors: Yan Zheng, Jiayan Ma, Xiaowei Feng, Mengyu Liu, Peixuan Chen, Zhisheng Guan, Longxu Xie, Yiyuan Ge
-
Publication number: 20230228667Abstract: The present invention discloses a method for isolating placental trophoblast cells from cervical exfoliated cells of a pregnant woman. Based on a specific antigen or combination expressed on the surface or inside of specific trophoblast cells, the designed microfluidic sorting chip or flow cytometer is used in the method to perform cell sorting of a cell suspension of a placental trophoblast sample, thus obtaining isolated and purified placental trophoblast cells. Compared with conventional methods, the method of the present invention has the advantages of non-invasively obtaining specimens and good specificity. Moreover, the method causes low risk of infection and abortion, allows earlier sampling time and can achieve the synchronous labeling of a plurality of antigens as well as identification and sorting of characteristic fluorescence signals; and the method has greatly improved accuracy and higher reliability and broader coverage area of detection results.Type: ApplicationFiled: March 16, 2022Publication date: July 20, 2023Applicants: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGDONG HYBRIBIO BIOTECH CO., LTD.Inventors: Yan ZHENG, Jiayan MA, Xiaowei FENG, Mengyu LIU, Peixuan CHEN, Zhisheng GUAN, Longxu XIE, Yiyuan GE
-
Patent number: 11564891Abstract: A product for preventing and treating external genitalia infection and/or flat warts is provided, wherein the product comprises a chloroquine nanosphere. The chloroquine nanosphere comprises a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative. A mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier during preparation ranges from 1:3 to 1:5. A loading rate of the chloroquine or the chloroquine derivative in the prepared chloroquine nanosphere ranges from 3.0% to 21.6%. The water-soluble nanosphere carrier is water-soluble chitosan; a deacetylation degree of the water-soluble chitosan ranges from 80% to 95%, and a viscosity-average molecular weight thereof ranges from 3000 to 5000 g/mol. The chloroquine derivative is selected from one or more of hydroxychloroquine, chloroquine phosphate or chloroquine sulfate.Type: GrantFiled: September 10, 2021Date of Patent: January 31, 2023Assignees: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.Inventors: Longxu Xie, Xiangling Li, Manli Yuan, Ting Wang, Jianyu Wang
-
Publication number: 20210401763Abstract: A product for preventing and treating external genitalia infection and/or flat warts is provided, wherein the product comprises a chloroquine nanosphere. The chloroquine nanosphere comprises a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative. A mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier during preparation ranges from 1:3 to 1:5. A loading rate of the chloroquine or the chloroquine derivative in the prepared chloroquine nanosphere ranges from 3.0% to 21.6%. The water-soluble nanosphere carrier is water-soluble chitosan; a deacetylation degree of the water-soluble chitosan ranges from 80% to 95%, and a viscosity-average molecular weight thereof ranges from 3000 to 5000 g/mol. The chloroquine derivative is selected from one or more of hydroxychloroquine, chloroquine phosphate or chloroquine sulfate.Type: ApplicationFiled: September 10, 2021Publication date: December 30, 2021Applicants: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.Inventors: Longxu XIE, Xiangling LI, Manli YUAN, Ting WANG, Jianyu WANG
-
Patent number: 11147773Abstract: A chloroquine gel and a preparation method and application thereof. A chloroquine nanosphere includes a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative, wherein a mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier is no more than 1:3.Type: GrantFiled: November 4, 2019Date of Patent: October 19, 2021Assignees: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.Inventors: Longxu Xie, Xiangling Li, Manli Yuan, Ting Wang, Jianyu Wang
-
Publication number: 20200397713Abstract: A chloroquine gel and a preparation method and application thereof. A chloroquine nanosphere includes a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative, wherein a mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier is no more than 1:3.Type: ApplicationFiled: November 4, 2019Publication date: December 24, 2020Applicants: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.Inventors: Longxu XIE, Xiangling LI, Manli YUAN, Ting WANG, Jianyu WANG